Many Americans are taking GLP1 medications, which include weight loss and diabetes medications Ozempic and Wegovy.

A Howard County man is suing Novo Nordisk, alleging Ozempic caused him to go blind after using the drug to treat diabetes. He seeks damages in court.

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

All these drugs are very effective and they’ve become a game changer for people who need to lose weight. Get on the drug, eat ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...

Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.

Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.

Janelle Rohner claims she still followed her diet plan, noting GLP-1 weight loss drugs "don’t change your lifestyle overnight ...

Two years on from The Royal Gazette’s first report on a new wave of diabetes drugs with broader health benefits, the island’s ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Leveraging AI, researchers have identified a naturally occurring molecule that can suppress appetite and facilitate weight loss in mice and pigs.

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...